Michael A Weber
#143,430
Most Influential Person Now
Researcher
Michael A Weber's AcademicInfluence.com Rankings
Michael A Webercomputer-science Degrees
Computer Science
#7029
World Rank
#7404
Historical Rank
Computational Linguistics
#1328
World Rank
#1343
Historical Rank
Machine Learning
#2466
World Rank
#2498
Historical Rank
Artificial Intelligence
#2751
World Rank
#2794
Historical Rank
Download Badge
Computer Science
Michael A Weber's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Michael A Weber Influential?
(Suggest an Edit or Addition)Michael A Weber's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (1994) (3667)
- Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. (2006) (2183)
- Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial (2004) (2115)
- Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. (2008) (1574)
- Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. (2014) (923)
- Feasibility of treating prehypertension with an angiotensin-receptor blocker. (2006) (894)
- ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. (2011) (888)
- Clinical Practice Guidelines for the Management of Hypertension in the Community (2014) (726)
- Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. (2003) (723)
- Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. (2008) (711)
- Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. (2007) (625)
- Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial (2004) (612)
- Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The value randomised trial☆ (2004) (599)
- Telmisartan to prevent recurrent stroke and cardiovascular events. (2008) (583)
- Critical issues in peripheral arterial disease detection and management: a call to action. (2003) (578)
- Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial (2017) (503)
- Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial (2018) (486)
- Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial (2010) (443)
- Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial (2018) (413)
- Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study (2009) (348)
- Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo (2008) (320)
- Global burden of cardiovascular disease and stroke: hypertension at the core. (2015) (305)
- Effects of the Selective Aldosterone Blocker Eplerenone Versus the Calcium Antagonist Amlodipine in Systolic Hypertension (2003) (291)
- A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial (2009) (288)
- Changes in albuminuria predict mortality and morbidity in patients with vascular disease. (2011) (247)
- May Measurement Month 2017: an analysis of blood pressure screening results worldwide. (2018) (229)
- Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials (2017) (228)
- Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial (2001) (218)
- Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial (2020) (217)
- Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals (2011) (189)
- Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension (2011) (188)
- May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension (2019) (182)
- Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial (2010) (170)
- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. (2016) (168)
- Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial (2006) (165)
- Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial (2006) (165)
- Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. (2013) (164)
- Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. (2004) (152)
- The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in Patients Receiving Monotherapy (2006) (148)
- Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. (2004) (141)
- Expanding the Definition and Classification of Hypertension (2005) (140)
- International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. (2013) (138)
- Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks (2018) (137)
- The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure (2011) (131)
- A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. (2003) (131)
- The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. (2016) (127)
- Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry (2016) (125)
- Exceptional early blood pressure control rates: The ACCOMPLISH trial (2007) (119)
- Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). (2009) (119)
- Cardiovascular events during differing hypertension therapies in patients with diabetes. (2010) (116)
- Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial (2013) (113)
- Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. (2012) (111)
- Adherence and persistence with taking medication to control high blood pressure. (2011) (103)
- Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring (2011) (102)
- Clinical applications of arterial stiffness: therapeutics and pharmacology. (2002) (98)
- Changes in ventricular septal thickness during diuretic therapy (1982) (93)
- Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial (2021) (93)
- The Role of the New β-Blockers in Treating Cardiovascular Disease (2005) (91)
- Efficacy and Safety of Darusentan in Patients With Resistant Hypertension: Results From a Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Study (2007) (90)
- VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk (2003) (88)
- Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. (2016) (87)
- Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial (2001) (86)
- Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockade (2016) (85)
- Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials (2018) (78)
- Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. (2012) (75)
- Angiotensin II Amplification of α‐Adrenergic Vasoconstriction: Role of Receptor Reserve (1988) (75)
- The Efficacy and Safety of Low‐ and High‐ Dose Fixed Combinations of Irbesartan/Hydrochlorothiazide in Patients With Uncontrolled Systolic Blood Pressure on Monotherapy: The INCLUSIVE Trial (2005) (74)
- Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. (2019) (73)
- The technical report on sodium intake and cardiovascular disease in low- and middle-income countries by the joint working group of the World Heart Federation, the European Society of Hypertension and the European Public Health Association. (2017) (72)
- The 24-hour blood pressure pattern: does it have implications for morbidity and mortality? (2002) (68)
- Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial (2007) (68)
- Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk (2007) (65)
- Outcome after out-of-hospital cardiac arrest in a physician-staffed emergency medical system according to the Utstein style. (2007) (65)
- Nocturnal blood pressure measured by home devices: evidence and perspective for clinical application (2018) (65)
- Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. (2004) (64)
- Clinical Expert Consensus Documents A Report of the American College of Cardiology Foundation Task Force on ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: (2011) (63)
- Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic Hypertension (2012) (60)
- Hypertension: A Companion to Brenner and Rector's The Kidney (2005) (59)
- Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. (2006) (59)
- Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? (2006) (57)
- No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial (2016) (57)
- TRANSDERMAL CONTINUOUS ANTIHYPERTENSIVE THERAPY (1984) (55)
- Efficacy of Combination Therapy for Systolic Blood Pressure in Patients With Severe Systolic Hypertension: The Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) Study (2005) (55)
- Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. (2008) (55)
- Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial (2019) (54)
- The ALLHAT Report: A Case of Information and Misinformation (2003) (53)
- A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. (2018) (53)
- Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. (2013) (53)
- VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. (2004) (52)
- Emergence of Home Blood Pressure-Guided Management of Hypertension Based on Global Evidence (2019) (52)
- Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? (2005) (52)
- Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies (2020) (52)
- Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study (2008) (52)
- Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence. (2019) (51)
- LIMITATIONS OF TRANSCENDENTAL MEDITATION IN THE TREATMENT OF ESSENTIAL HYPERTENSION (1977) (50)
- Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study (2014) (50)
- The role of the new beta-blockers in treating cardiovascular disease. (2005) (49)
- Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin ii receptor antagonists in the treatment of hypertension (1999) (45)
- A Randomized, Double‐Blind, Placebo‐Controlled Parallel‐Group Study to Assess the Efficacy and Safety of Nebivolol, a Novel β‐Blocker, in Patients With Mild to Moderate Hypertension (2007) (45)
- Efficacy and Duration of Benazepril Plus Amlodipine or Hydrochlorthiazide on 24-Hour Ambulatory Systolic Blood Pressure Control (2011) (44)
- The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) Programme (2003) (43)
- São Paulo call to action for the prevention and control of high blood pressure: 2020 (2019) (42)
- Changes in Plasma Renin Activity after Renal Artery Sympathetic Denervation. (2021) (41)
- Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies (2014) (41)
- Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension (2021) (41)
- Blood Pressure–Lowering Efficacy of the Fixed‐Dose Combination of Azilsartan Medoxomil and Chlorthalidone: A Factorial Study (2012) (40)
- A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. (2005) (40)
- ASH position paper: dietary approaches to lower blood pressure. (2010) (40)
- Antihypertensive Efficacy of Irbesartan/HCTZ in Men and Women With the Metabolic Syndrome and Type 2 Diabetes (2006) (39)
- Combination therapy in hypertension. (2010) (39)
- Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region (2005) (38)
- Antihypertensive Utility of Perindopril in a Large, General Practice‐Based Clinical Trial (2004) (37)
- Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. (2019) (37)
- Systemic hemodynamic atherothrombotic syndrome (SHATS) - Coupling vascular disease and blood pressure variability: Proposed concept from pulse of Asia. (2019) (37)
- The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension. (2020) (36)
- Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial (2005) (35)
- Controlled-release carvedilol in the treatment of essential hypertension. (2006) (34)
- High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Soci (2016) (33)
- Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. (2013) (33)
- Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy (2012) (32)
- Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. (2006) (32)
- Efficacy of a Once‐Daily Formulation of Carvedilol for the Treatment of Hypertension (2006) (31)
- Clinical implications of aldosterone blockade. (2002) (31)
- Renal outcomes in hypertensive Black patients at high cardiovascular risk. (2012) (31)
- Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) (30)
- Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy (2007) (29)
- Angiotensin Receptor Blocker and Dihydropyridine Calcium Channel Blocker Combinations: An Emerging Strategy in Hypertension Therapy (2009) (29)
- Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. (2020) (29)
- One-Year Study of Felodipine or Placebo for Stage 1 Isolated Systolic Hypertension (2001) (29)
- Physician (investigator) inertia in apparent treatment-resistant hypertension – Insights from large randomized clinical trials. Lennart Hansson Memorial Lecture (2015) (29)
- 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. (2020) (28)
- Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial. (2018) (27)
- 24-hour ambulatory blood pressure in the ACCOMPLISH trial. (2010) (27)
- Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. (2017) (26)
- The Metabolic Syndrome—What Is It and How Should It Be Managed? (2006) (26)
- Mild hypertension : from drug trials to practice (1987) (26)
- Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy (2016) (25)
- When and how to use self (home) and ambulatory blood pressure monitoring. (2010) (25)
- Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial. (2004) (25)
- Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. (2013) (24)
- Calcium Channel Antagonists in the Treatment of Hypertension (2002) (23)
- Quality of Life Measured in a Practice‐Based Hypertension Trial of an Angiotensin Receptor Blocker (2003) (23)
- Blood Pressure Effects of Combined β‐Blocker and Angiotensin‐Converting Enzyme Inhibitor Therapy Compared With the Individual Agents: A Placebo‐Controlled Study With Nebivolol and Lisinopril (2012) (22)
- Prevention of Microalbuminuria in Patients With Type 2 Diabetes: What Do We Know? (2010) (22)
- Is It Time to Reappraise Blood Pressure Thresholds and Targets? A Statement From the International Society of Hypertension-A Global Perspective. (2016) (22)
- Creating a Combination Antihypertensive Regimen: What Does the Research Show? (2003) (20)
- The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease. (2002) (20)
- Vasopeptidase inhibitors. Commentary (2001) (20)
- Effect of Combining Extended‐Release Carvedilol and Lisinopril in Hypertension: Results of the COSMOS Study (2010) (20)
- Progress and Controversies: Treating Obesity and Insulin Resistance in the Context of Hypertension (2009) (20)
- Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial (2022) (19)
- Confounding Factors in Renal Denervation Trials: Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for Hypertension. (2020) (19)
- Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right (2015) (18)
- Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial. (2002) (18)
- Treatment of hypertension in patients with diabetes--an update. (2009) (18)
- Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. (2003) (18)
- The Combined Alpha‐ and Beta‐Adrenergic Blocker Labetalol and Propranolol in the Treatment of High Blood Pressure: Similarities and Differences (1984) (18)
- Hypertension: Cardiovascular benefits of lowering blood pressure (2016) (18)
- Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. (2021) (18)
- ASH recommendations on the clinical use of home and ambulatory blood pressure monitoring (1995) (18)
- Treatment of patients with hypertension and arthritis pain: new concepts. (2009) (17)
- Recommended standards for assessing blood pressure in human research where blood pressure or hypertension is a major focus (2017) (17)
- Endogenous opioids and opiate antagonists modulate the blood pressure of the spontaneously hypertensive rat (1986) (17)
- THE ANTIHYPERTENSIVE PROPERTIES OF THE ANGIOTENSIN‐CONVERTING ENZYME INHIBITOR MOEXIPRIL GIVEN ALONE OR IN COMBINATION WITH A LOW DOSE OF A DIURETIC (1995) (17)
- Blood pressure measurement in special populations and circumstances (2018) (16)
- Angiotensin-II receptor blockers for hypertension and heart failure: quality of life and outcomes. (2005) (16)
- Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design (2020) (16)
- Non-invasive automated blood pressure monitoring in ambulatory normotensive men (1984) (16)
- Effects of naproxcinod on blood pressure in patients with osteoarthritis. (2011) (16)
- A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. (2007) (16)
- Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy (2019) (16)
- The Antihypertensive Efficacy and Safety of a Chronotherapeutic Formulation of Propranolol in Patients With Hypertension (2004) (15)
- Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial (2008) (15)
- Blood pressure variability and cardiovascular prognosis: implications for clinical practice (2017) (15)
- Self-measured (blood pressure) arterial stiffness index: A promising new measure of arterial stiffness. (2007) (15)
- Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. (2008) (15)
- New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. (2007) (14)
- Outcomes of treating hypertension in the elderly: a short commentary on current issues. (2003) (14)
- Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. (2015) (14)
- Circadian variations in cardiovascular disease: chronotherapeutic approaches to the management of hypertension. (2004) (13)
- The Accuracy in Measurement of Blood Pressure (AIM‐BP) collaborative: Background and rationale (2019) (13)
- Recently Published Hypertension Guidelines of the JNC 8 Panelists, the American Society of Hypertension/International Society of Hypertension and Other Major Organizations: Introduction to a Focus Issue of The Journal of Clinical Hypertension (2014) (13)
- Hypertension treatment and implications of recent cardiovascular outcome trials (2006) (13)
- Repetitive Blood Pressure Measurements: Clinical Issues, Techniques, and Data Analysis (1987) (13)
- Roundtable Discussion: Blood Pressure Lowering by Any Means, or Do Specific Medications Make a Difference? (2001) (12)
- Hypertension, the Metabolic Syndrome, and the Risk of Developing Diabetes: Is It Time to Change the Guidelines? (2004) (12)
- The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. (2008) (12)
- Cardiovascular protection for all individuals at high risk: evidence-based best practice (2008) (12)
- Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF (2021) (12)
- ALLHAT--all hit or all miss? Key questions still remain. (2003) (12)
- Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension (2014) (12)
- Cardiovascular Safety of the β3‐Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial (2018) (12)
- The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update. (2010) (12)
- Differing Roles of Body Mass and the Renin-Angiotensin System in Mediating the Hypertension Syndrome (2000) (12)
- β‐Blockers in the Treatment of Hypertension: New Data, New Directions (2008) (11)
- Review: Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold? (2003) (11)
- Global Implications of Blood Pressure Thresholds and Targets: Guideline Conversations From the World Hypertension League. (2018) (11)
- A repressive coping style protecting from emotional distress in low‐renin essential hypertensives (1994) (11)
- Blood pressure fluctuation and amplitude in normal human subjects (1984) (11)
- Abstract 13144: Effects of Dapagliflozin on Blood Pressure in Diabetic Patients With Hypertension Inadequately Controlled by a Renin-Angiotensin System Blocker (2013) (10)
- Efficacy of combination therapy with amlodipine besylate/benazepril hydrochloride for lowering systolic blood pressure in stage 2 hypertension. (2006) (10)
- Angiotensin-receptor blockade, cancer, and concerns. (2010) (10)
- Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial (2020) (10)
- SAFETY AND EFFICACY OF AGGRESSIVE BLOOD PRESSURE LOWERING AMONG PATIENTS WITH DIABETES: SUBGROUP ANALYSES FROM THE ONTARGET TRIAL (2009) (10)
- Clinical efficacy and safety profiles of AT1 receptor antagonists (1999) (10)
- Nocturnal hypertension in diabetes: Potential target of sodium/glucose cotransporter 2 (SGLT2) inhibition (2018) (10)
- COMPARISON OF ANTIHYPERTENSIVE EFFICACY OF THE NEW ANGIOTENSIN RECEPTOR BLOCKER AZILSARTAN MEDOXOMIL WITH RAMIPRIL: PP.16.112 (2010) (10)
- Managing the patient at risk for a second stroke (2005) (9)
- Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. (2021) (9)
- Chrono: A Community-Based Hypertension Trial of a Chronotherapeutic Formulation of Verapamil (2002) (9)
- Ambulatory Blood Pressure Monitoring: New Directions and Uncertainties Arise From the U.S. Preventive Services Task Force Recommendation on the Diagnosis of Hypertension (2016) (9)
- Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients (2018) (9)
- The Evolving Clinical Management of Hypertension (2014) (9)
- Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension? (2009) (9)
- Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation: A Post Hoc Analysis of the RADIANCE-HTN SOLO Study. (2020) (9)
- Low Dose Combination Therapy vs. High Dose Monotherapy in the Management of Hypertension. (1999) (9)
- Abstract 13165: Dapagliflozin for Reduction of Blood Pressure in Diabetic Patients Inadequately Controlled With Combination Antihypertensive Regimen (2013) (9)
- Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold? (2003) (9)
- Management of High Blood Pressure in Clinical Practice: Perceptible Qualitative Differences in Approaches Utilized by Clinicians (2008) (8)
- Yet more hypertension guidelines: what do they add? (2003) (8)
- Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension (2017) (8)
- Angiotensin II receptor blockers in older patients. (2004) (8)
- Overview of Fosinopril (1991) (8)
- Fluvastatin Lipid-Lowering Effect in Routine Practice Conditions (FLIRT) (1997) (8)
- Renal Denervation for the Treatment of Hypertension: Making a New Start, Getting It Right (2015) (8)
- Automated Blood-Pressure Measurements in the Diagnosis of Mild Hypertension (1986) (8)
- A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial (2018) (8)
- Contributions to Hypertension Public Policy and Clinical Practice: A Review of Recent Reports (2016) (8)
- Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium (2022) (8)
- P-255: Ambulatory blood pressure monitoring in the primary care setting: Assessment of therapy on circadian variation of blood pressure from the MICCAT-2 trial (2005) (8)
- ANTIHYPERTENSIVE EFFICACY OF THE NOVEL ANGIOTENSIN RECEPTOR BLOCKER AZILSARTAN MEDOXOMIL IN COMBINATION WITH AMLODIPINE: PP.16.99 (2010) (8)
- An Effectiveness Study Comparing Algorithm‐Based Antihypertensive Therapy With Previous Treatments Using Conventional and Ambulatory Blood Pressure Measurements (2006) (7)
- Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study (2021) (7)
- Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: Results from a 10-week, double-blind, placebo-controlled, dose-titration study (1999) (7)
- Academic Physicians Confront a Hostile World: The Creation of ACRE (2009) (7)
- Association of beta-blocker use with increased aortic wave reflection. (2008) (7)
- The Losartan Intervention for Endpoint Reduction (LIFE) Trial—Have Angiotensin‐Receptor Blockers Come of Age? (2002) (7)
- Hypertension in the Aging Patient: New Imperatives, New Options. (2000) (7)
- Prioritized Endpoints for Device-Based Hypertension Trials: the Win Ratio Methodology. (2020) (7)
- Massive Left Ventricular Mural Thrombosis With Consumption Coagulopathy in Congestive Heart Failure (2005) (6)
- Absence of placebo effect on the whole day ambulatory blood pressure bp (1990) (6)
- Blood Pressure–Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers (2020) (6)
- Impact of number of prescribed medications on visit-to-visit variability of blood pressure: implications for design of future trials of renal denervation (2015) (6)
- Clinical Pharmacology of Centrally Acting Antihypertensive Agents (1989) (6)
- Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective (2008) (6)
- Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients (2018) (6)
- Strategies for prevention of cardiovascular disease in adults with hypertension (2020) (6)
- Angiotensin II receptor blockers and cardiovascular outcomes: The evidence now and in the future (2001) (6)
- Interpreting blood pressure in young adults. (2015) (6)
- P-251: Nebivolol in the treatment of patients with stage 1 and stage 2 hypertension: Results of a randomized, double-blind, placebo-controlled study (2005) (6)
- A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension (2018) (5)
- BETA-BLOCKADE, RENIN AND BLOOD-PRESSURE (1977) (5)
- Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. (2019) (5)
- Treating hypertension in the elderly: protagonist viewpoint. (2003) (5)
- Angiotensin II Receptor Blockers (2001) (5)
- Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. (2018) (5)
- Report on Round Table on renin suppression and the hypotensive action of beta-adrenergic-blocking drugs. (1975) (5)
- Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors. (2003) (5)
- Septal thickness as a marker of changes in left ventricular muscle mass during short-term therapy with hydrochlorothiazide (1982) (5)
- REDUCED BLOOD PRESSURE LOWERING EFFECT OF CATHETER-BASED RENAL DENERVATION IN PATIENTS WITH ISOLATED SYSTOLIC HYPERTENSION: DATA FROM POOLED SYMPLICITY HTN TRIALS (2015) (5)
- P-431: Design of the accomplish (avoiding cardiovascular events through combination therapy in patients living with systolic hypertension) trial (2003) (5)
- Beta-blocker therapy in hypertension: a need to pause and reflect. (2008) (5)
- How Well Do We Care for Patients With Hypertension? (2012) (5)
- Blood Pressure Goal Attainment: Meeting the Challenge of the JNC 7's Blood Pressure Goals and the Role of Renin‐Angiotensin‐Aldosterone System Blockade (2004) (5)
- Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial (2022) (5)
- P-373: A comparison of the effects of amlodipine 5 mg/benazepril 20 mg combination therapy to component monotherapy on arterial distensibilitly and left ventricular hypertrophy in patients with mild to moderate hypertension (2002) (4)
- Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension (2021) (4)
- Antihypertensive monotherapy with tablet (Prompt-release) diltiazem: Multicenter controlled trials (1990) (4)
- RESULTS OF A NOVEL ANGIOTENSIN RECEPTOR BLOCKER, AZILSARTAN MEDOXOMIL, IN PATIENTS WITH PRIMARY HYPERTENSION: 9A.01 (2010) (4)
- Treatment of elderly hypertensive patients with a delayed-release verapamil formulation in a community-based trial. (2004) (4)
- Angiotensin II and trials of cardiovascular outcomes. Discussion (2002) (4)
- Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study (2012) (4)
- Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial (2021) (4)
- THE NEW ANGIOTENSIN RECEPTOR BLOCKER AZILSARTAN MEDOXOMIL HAS SIGNIFICANTLY GREATER 24-HOUR BLOOD PRESSURE LOWERING EFFICACY TO BOTH OLMESARTAN AND VALSARTAN: 9D.05 (2010) (4)
- Blood pressure measurement reliability among different racial-ethnic groups in a stroke prevention study (2014) (4)
- Association of Clinical Researchers and Educators a statement on relationships between physicians and industry. (2012) (4)
- Building the case for central blood pressure. (2013) (4)
- Clinical Experience with Perindopril in Elderly Hypertensive Patients (2004) (4)
- Management of High‐Risk Hypertensive Patients with Diabetes: Potential Role of Angiotensin II Receptor Antagonists (2001) (4)
- Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trial (2015) (4)
- Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial (2022) (4)
- Telmisartan in high-risk cardiovascular patients. (2010) (4)
- THE NITRIC OXIDE DONATOR NAPROXCINOD HAS BLOOD PRESSURE EFFECTS SIMILAR TO PLACEBO IN PATIENTS ON RENIN-ANGIOTENSIN SYSTEM BLOCKERS: 9D.02 (2010) (4)
- TACHYCARDIA IS A STRONG PREDICTOR OF CARDIOVASCULAR EVENTS IN THE VALUE TRIAL: 6A.04 (2010) (4)
- 558 AZILSARTAN MEDOXOMIL VS OLMESARTAN AND VALSARTAN: EFFECTS ON AMBULATORY AND CLINIC BP IN HYPERTENSIVE BLACK PATIENTS (2012) (4)
- P-198: A factorial design to assess the safety and efficacy of olmesartan medoxomil and hydrochlorothiazide combination therapy (2003) (4)
- Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk (2021) (4)
- New Results and Analyses Expand and Modify Key Interpretations of the ALLHAT Trial (3)
- Introduction: the hemodynamic and vascular effects of angiotensin II: managing the consequences. (2002) (3)
- The use of chronotherapeutics to achieve maximal blood pressure reduction during the early morning blood pressure surge (1999) (3)
- Correction to: Rationale and design of two randomized sham‑controlled of catheter‑based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN‑OFF MED Pivotal) and presence (SPYRAL HTN‑ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian (2020) (3)
- Renal outcomes with diff erent fi xed-dose combination therapies in patients with hypertension at high risk for cardiovascular events ( ACCOMPLISH ) : a prespecifi ed secondary analysis of a randomised controlled trial (2010) (3)
- Initial combination therapy in older patients with systolic hypertension: results of the systolic evaluation of lotrel efficacy and comparative therapies (select) study (2004) (3)
- Hypertension in the Elderly (2000) (3)
- Immediate Treatment of Severe Hypertension (1989) (3)
- The potential role of nitric oxide in cardiovascular safety when treating patients with osteoarthritis and hypertension: a moderated panel discussion. (2009) (3)
- Hypertension Guidelines: A Major Reappraisal Critically Examines the Available Evidence (2010) (3)
- CHANGES IN ALBUMINURIA PREDICT MORTALITY AND MORBIDITY IN PATIENTS WITH VASCULAR DISEASE: PS.3.04 (2010) (3)
- Mediators of Changes in Left Ventricular Mass During Antihypertensive Therapy (1983) (3)
- The Evolution of Combination Therapy in Treating Hypertension (2007) (3)
- Vasopeptidase inhibitors (2001) (3)
- Exploring Issues in Difficult‐to‐Treat Hypertension (2013) (3)
- A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone (2018) (3)
- Cardiovascular characteristics of normotensive adolescents with a family history of hypertension (1990) (3)
- Renal denervation for the treatment of hypertension: Making a new start, getting it right (2015) (3)
- Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension (2021) (3)
- Long-term effects of 3 months blood pressure telemonitoring in inadequately treated patients with hypertension (2009) (3)
- Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk (2021) (3)
- Eff ects of body size and hypertension treatments on cardiovascular event rates : subanalysis of the ACCOMPLISH randomised controlled trial (2012) (3)
- The Journal of Clinical Hypertension Has Become the Official Journal of the World Hypertension League (2014) (2)
- Methodological and Regulatory Considerations for Updated Guidance on the Pressor Effects of Drugs (2020) (2)
- P-250: Efficacy and safety of fixed combinations of irbesartan/HCTZ in patients with uncontrolled SBP on monotherapy, according to previous antihypertensive drug class, in the inclusive trial (2005) (2)
- Tolerability profile of tasosartan, a long-acting angiotensin II AT1 receptor blocker, in the treatment of patients with essential hypertension (1997) (2)
- RADIANCE-HTN SOLO: A MULTICENTER, RANDOMIZED, SHAM-CONTROLLED STUDY OF RENAL DENERVATION IN PATIENTS WITH UNCONTROLLED HYPERTENSION IN THE ABSENCE OF ANTIHYPERTENSIVE MEDICATIONS (2018) (2)
- CLINICAL AND COST EFFECTIVENESS OF RENAL DENERVATION WITH THE VESSIX SYSTEM IN PATIENTS WITH RESISTANT HYPERTENSION (2014) (2)
- The effects on dementia of long-term treatment of hypertension. (2003) (2)
- Clinical effectiveness of the transdermal route of antihypertensive treatment (1984) (2)
- TREATMENT-BLINDED MEDICATION TITRATION FOR HYPERTENSION CONTROL FOLLOWING RANDOMIZATION TO ENDOVASCULAR ULTRASOUND RENAL DENERVATION OR A SHAM PROCEDURE (2019) (2)
- P-411: Management of isolated vs. predominantly systolic hypertension: results of the systolic evaluation of lotrel efficacy and comparative therapies (select) study (2004) (2)
- Hypertension management in patients with cardiovascular comorbidities. (2022) (2)
- Global cardiovascular disease prevention and management: A collaboration of key organizations, groups, and investigators in low‐ and middle‐income countries (2020) (2)
- Development of the certificate course in the management of hypertension in Africa (CCMH-Africa): proceedings of the first continental faculty meeting, Nairobi, Kenya, 25-26 February 2018. (2018) (2)
- Alcohol-mediated renal sympathetic neurolysis for the treatment of hypertension: The Peregrine™ infusion catheter. (2020) (2)
- NEW ANGIOTENSIN II RECEPTOR BLOCKER AZILSARTAN MEDOXOMIL: COMPARISON TO VALSARTAN: PP.16.88 (2010) (2)
- Guidelines for Home Blood Pressure Monitoring (2019) (2)
- Changes in blood pressure after crossover to ultrasound renal denervation in patients initially treated with sham in the RADIANCE-HTN SOLO trial. (2021) (2)
- Aldosterone: Possible Roles in Sustaining Essential Hypertension and in Determining Response to Antihypertensive Treatment (1981) (2)
- Cardiovascular Benefits of Angiotensin Converting Enzyme Inhibition plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and with Resistant Hypertension. (2020) (2)
- A new mandate for treating hypertension in the elderly (2008) (2)
- TCT-29 Procedural and anatomic predictors of response in RADIANCE-HTN SOLO: a multicenter, randomized, sham-controlled trial of endovascular ultrasound renal denervation (2018) (2)
- Exploring a New Definition of Hypertension (2)
- Expanding the opportunities for blocking the renin-angiotensin system: introduction to a special supplement. (2007) (2)
- A Multicenter Study on the Use of Transdermal Clonidine in Patients with Essential Hypertension (1985) (2)
- SAFETY AND EFFICACY OF LOW BLOOD PRESSURE AMONG PATIENTS WITH DIABETES: SUB-GROUP ANALYSES FROM THE ONTARGET TRIAL: 7E.02 (2011) (2)
- Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. (2016) (2)
- Evaluation of the 24 h effects of the angiotensin II receptor blockers: means to improve cardiovascular outcomes? (2003) (2)
- Effects of the novel melanocortin receptor agonist bremelanotide on ambulatory blood pressure and heart rate in women with sexual dysfunction (2014) (2)
- Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk (2022) (2)
- THE THERAPEUTIC IMPLICATIONS OF LEFT VENTRICULAR HYPERTROPHY IN THE HYPERTENSIVE PATIENT (1995) (2)
- Improved Understanding of Renal Nerve Anatomy: An Opportunity to Enhance Denervation Treatment of Hypertension. (2021) (2)
- Optimum antihypertensive therapy: does adiposity matter? (2015) (2)
- A044: A dynamic delivery system designed for bedtime dosing enhances verapamil levels and blood pressure reductions in the morning (2000) (1)
- Building research capacity within cardiovascular disease prevention and management in low‐ and middle‐income countries: A collaboration of the US Centers for Disease Control and Prevention, the Lancet Commission on Hypertension Group, Resolve to Save Lives, and the World Hypertension League (2021) (1)
- Abstract 13640: Dapagliflozin Lowers HbA1c, Systolic Blood Pressure and Serum Uric Acid in Patients With Type 2 Diabetes and Hypertension, Regardless of Class of Concomitant Antihypertensive Therapy (2014) (1)
- Reducing cardiovascular and cerebral events (2002) (1)
- P-23: Effect of perindopril erbumine, an angiotensin converting enzyme inhibitor (ACE-I), on blood pressure in patients with mild to moderate hypertension - a large Aceon® Community Trial (ACT) with 8083 patients (2002) (1)
- Second Consensus on Treatment of Patients Recently Diagnosed With Mild Hypertension and Low Cardiovascular Risk. (2020) (1)
- Effects of treatment for hypertension on cognitive function in the elderly. (2006) (1)
- The ''RADIANCE-HTN'' clinical study: a two-cohort study design to evaluate the effectiveness of the paradise renal denervation system in patients with hypertension (2016) (1)
- Chronotherapeutic oral drug absorption system verapamil is effective in reducing morning blood pressure in African Americans: a post hoc analysis of the chrono trial. (2005) (1)
- Abstract 109: Changes in Plasma Renin Activity After Renal Denervation in the Spyral Htn-Off Med Trial (2019) (1)
- A new dawn in cardiovascular protection: blood pressure lowering through AT1 blockade. Introduction. (2003) (1)
- P-66: Efficacy of an olmesartan medoxomil-based treatment algorithym for hypertension control in practice-based settings (2002) (1)
- Darusentan treatment significantly decreases blood pressure and results in better systolic blood pressure control when added to multi-drug therapy in patients with resistant hypertension (2009) (1)
- Putting LIFE into hypertension (2002) (1)
- Angiotensin receptor blockers might have a role in treating diastolic heart failure (2003) (1)
- The Physician Payments Sunshine Act: A Setback for Medical Progress (2012) (1)
- [Drug therapy of hypertension]. (1951) (1)
- Expanding the Scope of Hypertension: Are We Creating New Diseases? (2006) (1)
- How Far to Reduce Blood Pressure in Patients With Diabetes—Even After ACCORD, Questions Remain (2010) (1)
- Introduction: Hypertension: Meeting therapeutic challenges, providing effective management (1991) (1)
- Hypertension, 2nd Edition (2006) (1)
- Wednesday, May 14, 10:00 AM-12:00 PM-Achieving Blood Pressure Goals: Is Fixed-Dose Combination Therapy the Answer?: How should combination therapy be started? (2003) (1)
- Olmesartan‐based monotherapy vs combination therapy in hypertension: A meta‐analysis based on age and chronic kidney disease status (2017) (1)
- Clinical Trials Report (2004) (1)
- P-453 *Program Revision (see p. 267A): Gender specific characteristics of 15,288 hypertensive patients at high coronary risk. The value trial (2001) (1)
- Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke (2021) (1)
- Hypertension research from Japan: advancing the field of renal denervation (2021) (1)
- The new wave of Asia: A major step forward in confronting global hypertension (2020) (1)
- Diagnosis ofMildHypertension byAmbulatory BloodPressure Monitoring (1994) (1)
- HYPERTENSION: a companion to brenner & rector's the kidney (2017) (1)
- The Human Side of Failed Hypertension Treatment (2013) (1)
- P-263: Comparative dose-response and safety of eplerenone, enalapril, losartan, and amlodipine in patients with essential hypertension (2003) (1)
- A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions (2021) (1)
- A Tribute to Dr John H. Laragh (2015) (1)
- Abstract 070: Adherence to Antihypertensive Drugs: Insights from the SPYRAL HTN Trials and Implications for Hypertension Trial Design (2018) (1)
- Nocturnal Home Blood Pressure Monitoring (2019) (1)
- Impact of Renal Pelvic Denervation on Systemic Hemodynamics and Neurohumoral Changes in a Porcine Model (2021) (1)
- The Importance of Prompt Blood Pressure Control to Target in High Risk Hypertensive Patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial (2004) (1)
- Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. (2022) (1)
- Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial. (2023) (1)
- First‐Step Use of Fixed‐Dose Combination Treatment in Stage 2 Hypertensive Patients: Has the Time Come? (2007) (1)
- Turning Attention to the Young (2011) (1)
- The JNC 7 Report: Challenges and Dilemmas in Writing Guidelines (2003) (1)
- Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials. (2023) (1)
- COMBINATION TREATMENT WITH SUSTAINED‐RELEASE VERAPAMIL AND INDAPAMIDE IN THE TREATMENT OF MILD‐TO-MODERATE HYPERTENSION (1996) (1)
- ONTARGET: Questions Asked, Questions Answered (2008) (1)
- Antihypertensive therapy and quality of life. (1987) (0)
- Blood Pressure Mechanisms and the Sympathetic Nervous System (1989) (0)
- Darusentan lowers blood pressure significant on top of multi-drug treatment in patients with resistant hypertension (2009) (0)
- Inhibiting the renin-angiotensin system: Differing therapeutic strategies to optimize RAS blockade (2005) (0)
- Differing cardiovascular and neuroendocrine profiles in obese and lean hypertensive patients (2000) (0)
- In Memoriam: Alberto Zanchetti (Parma July 27, 1926 – Milan March 24, 2018) (2018) (0)
- Clinical Trials Report (2005) (0)
- Introduction. The cardiovascular continuum in the 21st century: renin-angiotensin system blockade, the cardiovascular continuum in the 21st century. (2010) (0)
- A045: The antihypertensive effects of diltiazem 420 MG. A comparrison of once daily delivery systems (2000) (0)
- Does the Concept of a Hypertension Syndrome Apply in the Aging? (1992) (0)
- Addressing Gaps in Our Knowledge of the Angiotensin Receptor Blockers: Report of a Roundtable (2009) (0)
- Hypertension: BP reduction in patients with diabetes—uncertainties remain (2010) (0)
- Obesity, blood pressure, and cardiovascular outcomes – Authors' reply (2013) (0)
- Cardiovascular Risk Factor Profile of Hypertension: Therapeutic Approaches (1992) (0)
- Abstract P154: Win Ratio Methodology Demonstrates Consistency Of Benefit Across Different Blood Pressure Reduction Thresholds Following Renal Denervation In The Spyral Htn-on Med Pilot Study (2021) (0)
- RELATIONSHIPS BETWEEN SYSTOLIC BLOOD PRESSURE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH HIGH RISK HYPERTENSION: AN ANALYSIS OF THE ACCOMPLISH TRIAL (2013) (0)
- Blood pressure analyses from 25 595 patients (from 25 620 randomised) during the ONTARGET trial: reflections on current guidelines (2008) (0)
- Treating hypertension: who speaks for the patient? (2021) (0)
- PL 02-3 MANAGEMENT OF ELDERLY HYPERTENSION: WHOM TO TREAT AND HOW LOW TO GO. (2016) (0)
- Inhibiting Both RAS and SNS for High Blood Pressure Control: Myths and Facts. (2000) (0)
- A large-scale ambulatory blood pressure monitoring (ABPM) trial in the practice setting: efficacy of the angiotensin receptor blocker, telmisartan (2004) (0)
- D012 Valsartan antihypertensive longterm use evaluation (the value study) (1998) (0)
- TCT-608 Implementation of Bayesian Study Design in the SPYRAL HTN-OFF MED Pivotal Trial (2019) (0)
- PATIENT PREFERENCES FOR PHARMACEUTICAL AND INTERVENTIONAL HYPERTENSION TREATMENTS: RESULTS FROM A DISCRETE CHOICE EXPERIMENT (2022) (0)
- Measuring the Benefits of Antihypertensive Treatment (2001) (0)
- Evaluating Risks and Events in Hypertension: An Overview of the Hypertension Syndrome (1997) (0)
- Body mass determines clinical outcomes of antihypertensive treatment (2000) (0)
- I38 - Differences in exercise induced metabolic changes in norhotensive patients with and without a family history of hypertension (1995) (0)
- S-26-1: LESSONS LEARNED ABOUT HYPERTENSION FROM RENAL DENERVATION CLINICAL TRIALS (2023) (0)
- Continuing Medical Education Program in The Journal of Clinical Hypertension (2011) (0)
- P-314: Hypertension control rates and hypertensive subtypes in the year 2000: an analysis comparing the clinics-based path and population-based NHANES III surveys (2002) (0)
- Comprar Hypertension Medicine | Prisant, Michael | 9781588298768 | Springer (2008) (0)
- Concluding comments: Hypertension (1985) (0)
- The use of combination therapy vs monotherapy in elderly systolic dipper vs systolic nondipper patients (2004) (0)
- CRT-300.01 Performance Characteristics of Alcohol-Mediated Endovascular Renal Denervation (2016) (0)
- Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial (2022) (0)
- Hypertension in Asia 2021: A major contribution to worldwide understanding and management of hypertension (2021) (0)
- Applicationsof AmbulatoryBloodPressureMonitoringin Clinical Practice (1991) (0)
- Starting Hypertension Treatment: Setting Targets (2000) (0)
- Combination Treatment with Sustained-Release Verapamil and Indapamide in the Treatment of Mild-to-Moderate Hypertension. (1996) (0)
- Insights Into Escape Patients in the SPYRAL HTN-OFF MED Pivotal Trial (2021) (0)
- When can treatment of hypertension be stopped? (2001) (0)
- Clinical trials report (2006) (0)
- Roundtable Discussion: The ALLHAT Trial (2003) (0)
- OR-32: Clinical experience with perindopril, an angiotensin converting enzyme inhibitor (ACEI), in U.S. hypertensive patients - a large community-based trial (2003) (0)
- S-10-3: CAN ACHIEVED AVERAGE SYSTOLIC BLOOD PRESSURE BELOW 130 MMHG CAUSE HARM IN ELDERLY HYPERTENSIVE PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY? (2023) (0)
- Erratum to: Structural, procedural and personnel prerequisites for outpatient vs. inhospital provision of cardiological services (2023) (0)
- The Role of the Sympathetic Nervous System in the Control of Left Ventricular Mass in Hypertension (1985) (0)
- Measurement of Blood Pressure in Clinical Practice. (2021) (0)
- P-175: Treatment of stage 1 and stage 2 hypertension (HTN) utilizing an olmesartan medoxomil (OM)-based treatment algorithm (2005) (0)
- Antihypertensive Utility of Perindopril in a Large, General Practice‐Based Clinical Trial (2005) (0)
- NONINVASIVE 24-HOUR HEMODYNAMICS PREDICT BLOOD PRESSURE RESPONSE TO RENAL DENERVATION IN THE SPYRAL HTN-OFF MED PILOT AND PIVOTAL TRIALS (2021) (0)
- Fluid retention and heart failure in the PRECISION trial – Authors' reply (2023) (0)
- Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension. (2008) (0)
- Importance of Consistent 24‐Hour Blood Pressure Control (2000) (0)
- MINERALOCORTICOIDS IN ESSENTIAL AND SECONDARY HYPERTENSION INTRODUCTION TO THE SYMPOSIUM (1982) (0)
- Antihypertensive therapy: How much blood pressure reduction is required and for which patients? (1995) (0)
- Meta-analysis of olmesartan medoxomil (OM) monotherapy in reducing blood pressure (BP) in elderly patients with hypertension (HTN) (2015) (0)
- Prior antihypertensive regimen usage and the cardiovascular risk reduction derived from combination therapy with angiotensin converting enzyme inhibition-calcium channel blockade: a secondary analysis of the avoiding cardiovascular events through combinat (2014) (0)
- Is There More to Life Than Blood Pressure? (2005) (0)
- The 24-hour blood pressure pattern: Does it have implications for morbidity and mortality? Discussion (2002) (0)
- ETC-1002 Reduces Blood Pressure in Hypercholesterolemic Patients with Mildly Elevated Blood Pressure (2014) (0)
- P-49: Difficulties in diagnosis: systolic hypertension in clinical practice (2003) (0)
- Abstract 20076: Effect of Combination Therapy with Benazepril/Amlodipine Compared with Benazepril/Hydrochlorothiazide in Patients with High-Risk, Stage 2 Hypertension with or Without Known Coronary Artery Disease (2010) (0)
- Abstract 16107: Combined HbA1c and Systolic Blood Pressure Reduction With Dapagliflozin in Patients With Both Inadequately Controlled Type 2 Diabetes Mellitus and Hypertension (2014) (0)
- Gaps in the Angiotensin Receptor Blocker (ARB) Knowledge Base (2010) (0)
- CRT-300.14 Patients’ Tolerance for Risks Associated With Interventional or Pharmaceutical Hypertension Treatment: Results From a Discrete Choice Experiment Study (2022) (0)
- Message from the Editor in Chief (2011) (0)
- Clinical trials report. Vascular effects beyond blood pressure: the CAMELOT study. (2005) (0)
- Efficacy and safety of nebivolol and valsartan in fixed-dose combinations in patients with stage 1 or 2 hypertension (2014) (0)
- Will the Systolic Blood Pressure Intervention Trial (SPRINT) change Treatment Targets in Hypertension (2016) (0)
- Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation (2022) (0)
- Benefits of treating hypertension: the Clinical Trialists Collaboration Group (2004) (0)
- Mechanisms of Action and Use of Newer Antihypertensive Agents (1984) (0)
- John Laragh and the renin thesis: creating a paradigm. (2014) (0)
- Secondary analysis of the VALUE trial: Intriguing new questions (2007) (0)
- Starting Hypertension Treatment (2001) (0)
- Similarities and Differences among Recent Hypertension Guidelines (2015) (0)
- MY APPROACH to the patient with hard-to-control hypertension. (2015) (0)
- Intensive treatment of hypertension to a SBP <120 mm Hg in patients aged 75 and over reduces mortality and cardiovascular events (2016) (0)
- OR-74: Once nightly dosing and steady state pharmacokinetics of circadian extended-release propranolol hydrochloride in patients with essential hypertension (2003) (0)
- An endothelin antagonist for resistant hypertension – Authors' reply (2010) (0)
- Data at 36 months for the Symplicity SPYRAL HTN-ON MED pilot – Authors' reply (2022) (0)
- P-71: Results of a community-based trial of a chronotherapeutic verapamil formulation (2002) (0)
- A Dramatic Addition to The Journal of Clinical Hypertension (2009) (0)
- Transurethral Renal Pelvic Denervation: A Feasibility Trial in Patients with Uncontrolled Hypertension (2022) (0)
- Remembering Dr Marvin Moser (2015) (0)
- CRT-300.13 U.S. Patient Preferences for Interventional and Pharmaceutical Hypertension Treatments: Initial Subgroup Analyses (2022) (0)
- Plasma renin activity and aldosterone levels in patients with hypertension receiving fixed-dose combination of nebivolol and valsartan: substudy of a phase 3 randomized trial (2014) (0)
- PL 02-3 MANAGEMENT OF ELDERLY HYPERTENSION: WHOM TO TREAT AND HOW LOW TO GO. (2016) (0)
- Best of the ESC Congress 2008 (0)
- S-35-6: LONG-TERM REDUCTION IN MORNING AND NIGHTTIME BLOOD PRESSURE AFTER RENAL DENERVATION: 36-MONTH RESULTS FROM SPYRAL HTN-ON MED PILOT TRIAL (2023) (0)
- Sustained-releaseNicardipinein Mild-to ModerateHypertension * (0)
- A COMMENTARY ON THE 2013 ESH/ESC GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION (2014) (0)
- Patient Preferences for Pharmaceutical and Device-Based Treatments for Uncontrolled Hypertension: Discrete Choice Experiment (2022) (0)
- ACCOMPLISH trial Design and rationale (2003) (0)
- CARDIOVASCULAR OUTCOMES AT RECOMMENDED BLOOD PRESSURE TARGETS IN MIDDLE AGED AND ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS AND HYPERTENSION (2021) (0)
- FIXED-DOSE COMBINATION OF AZILSARTAN MEDOXOMIL/CHLORTHALIDONE PROVIDES SUPERIOR BP REDUCTION TO MONOTHERAPIES IN STAGE 2 HYPERTENSION: PP.14.382 (2011) (0)
- EFFECT OF RENAL DENERVATION IN ATTENUATING THE MORNING SURGE IN BLOOD PRESSURE (2019) (0)
- A043: The pharmacokinetic and hemodynamic effects of once daily diltiazem delivery systems (2000) (0)
- Fixed-dose combination of nebivolol and valsartan in patients with stage 1 or 2 hypertension: ABPM substudy of a phase 3 randomized trial (2014) (0)
- 784 WHAT ARE THE EVIDENCE-BASED TARGETS OF BLOOD PRESSURE TREATMENT? ARE THE GUIDELINES CHANGING? (2012) (0)
- Role of calcium-channel blockers for treating hypertension in the 1990s. Roundtable discussion (1990) (0)
- Abstract 20657: The Incidence and Risk of Hypokalemia in Patients With High Risk Hypertension: The ACCOMPLISH Study (2010) (0)
- Abstract 10123: Evidence Against the J-shaped Curve in Treated Hypertensive Patients With Increased Cardiovascular Risk: The VALUE Trial (2015) (0)
- Introduction-prevention and management of cardiovascular and renal disease in diabetes (2001) (0)
- Clinical Trials Report (2003) (0)
- Progress in treating hypertension. (2008) (0)
- Introduction (2001) (0)
- Clinical trials report. Consequences of new-onset diabetes during the treatment of hypertension. (2004) (0)
- Chapter 38 – The Metabolic Syndrome (2007) (0)
- B027: A prospective, randomized, open-label, blinded endpoint, parallel group pilot study comparing the effects of quinapril and losartan on arterial stiffness in patients with mild to moderate hypertension (AC/DC) (2000) (0)
- AZILSARTAN MEDOXOMIL/CHLORTHALIDONE FIXED-DOSE COMBINATION LOWERS BP MORE THAN OLMESARTAN/HYDROCHLOROTHIAZIDE FIXED-DOSE COMBINATION IN STAGE 2 SYSTOLIC HYPERTENSION: LB3.4 (2011) (0)
- Wednesday, May 14, 4:00 PM-6:00 PM-New Therapeutic Strategies to Optimize Blood Pressure Control and End-Organ Protection*: Hypertension control with angiotensin II receptor blockers: strategies utilizing titration and combination (2003) (0)
- Response to “Opportunistic Screening for Atrial Fibrillation During Follow‐Up of Treated Hypertension” (2014) (0)
- PD66-11 EFFECTS OF VIBEGRON ON AMBULATORY BLOOD PRESSURE IN PATIENTS WITH OVERACTIVE BLADDER: RESULTS FROM A DOUBLE-BLIND STUDY (2021) (0)
- EFFECTS OF SINGLE OR MULTIPLE DRUG THERAPIES ON CARDIOVASCULAR OUTCOMES IN HYPERTENSION: ANALYSIS OF DATA FROM THE VALUE TRIAL: 6C.04 (2011) (0)
- EFFICACY AND SAFETY OF AZILSARTAN MEDOXOMIL/CHLORTHALIDONE WITH OLMESARTAN/HYDROCHLOROTHIAZIDE COMBINATIONS IN STAGE 2 SYSTOLIC HYPERTENSION: 4A.09 (2011) (0)
- A Message From the New Editor (2009) (0)
- Who is an expert? Reply (2017) (0)
- Hypertension in practice (1987) (0)
- Abstract 2584: Darusentan Significantly Reduces Systolic Blood Pressure in Patients with Resistant Hypertension on 4 or More Antihypertensive Drugs (2006) (0)
- BLOOD PRESSURE EFFECTS OVER TIME OF BIPOLAR RADIOFREQUENCY RENAL DENERVATION IN UNTREATED HYPERTENSION (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael A Weber?
Michael A Weber is affiliated with the following schools:
